Contineum Therapeutics, Inc. Class A Common Stock Financial Flexibility Index
Contineum Therapeutics, Inc. Class A Common Stock financial flexibility index. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Financial Flexibility Index of -1.07x as of June 2026. Free cash flow of $-11.49 Million (operating CF $-11.50 Million minus capex $6.00K) represents -1% of total liabilities ($10.71 Million). See cash generation quality of Contineum Therapeutics, Inc. Class A Com to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Financial flexibility index of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. Historical Financial Flexibility Index trend for Contineum Therapeutics, Inc. Class A Common Stock across 5 annual periods. Check CTNM cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Contineum Therapeutics, Inc. Class A Common Stock Financial Flexibility Index by Year (2021–2025)
Contineum Therapeutics, Inc. Class A Common Stock financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for Contineum Therapeutics, Inc. Class A Common Stock. For the full cash flow conversion analysis, see CTNM cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.52x | $-55.08 Million | $-55.31 Million | $15.65 Million | ▼ -60.9% |
| 2024 | -2.19x | $-32.33 Million | $-32.84 Million | $14.78 Million | ▼ -2295.0% |
| 2023 | 0.10x | $19.76 Million | $19.35 Million | $198.32 Million | ▲ +105.7% |
| 2022 | -1.76x | $-20.00 Million | $-20.12 Million | $11.37 Million | ▲ +39.8% |
| 2021 | -2.92x | $-26.10 Million | $-26.27 Million | $8.93 Million | — |